Get started

Seagen (United States)

Homepage: seagen.com
Alternate name: Seattle Genetics (United States)
Child institution: Seagen (Canada)
ROR: 01vwesc15
OpenAlex ID: I99319750
VEGF Inhibition and Renal Thrombotic Microangiopathy
2008 · Vera Eremina, J. Ashley Jefferson, et al. · New England Journal of Medicine · 1,504
PDF
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
2010 · Anas Younes, Nancy L. Bartlett, et al. · New England Journal of Medicine · 1,368
PDF
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
2019 · Rashmi K. Murthy, Sherene Loi, et al. · New England Journal of Medicine · 1,321
PDF
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
2004 · Kevin J. Hamblett, Peter D. Senter, et al. · Clinical Cancer Research · 1,249
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
2021 · Thomas Powles, Jonathan E. Rosenberg, et al. · New England Journal of Medicine · 1,230
PDF
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
2003 · Svetlana O Doronina, Brian E Toki, et al. · Nature Biotechnology · 1,206
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2024 · Thomas Powles, Begoña P. Valderrama, et al. · New England Journal of Medicine · 1,103
Potent antibody therapeutics by design
2006 · Paul J. Carter · Nature reviews. Immunology · 1,100
Arming antibodies: prospects and challenges for immunoconjugates
2005 · Anna M Wu, Peter D Senter · Nature Biotechnology · 1,052
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
2012 · Barbara Pro, Ranjana Advani, et al. · Journal of Clinical Oncology · 997
PDF
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
2003 · Joseph A. Francisco, Charles G. Cerveny, et al. · Blood · 931
Specificity of Leptin Action on Elevated Blood Glucose Levels and Hypothalamic Neuropeptide Y Gene Expression in ob/ob Mice
1996 · Michael W Schwartz, Denis G Baskin, et al. · Diabetes · 914
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
2007 · Farbod Shojaei, Xiumin Wu, et al. · Nature Biotechnology · 850
Antibody–drug conjugates come of age in oncology
2023 · Charles Dumontet, Janice M. Reichert, et al. · Nature Reviews Drug Discovery · 843
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
2017 · Joseph M. Connors, Wojciech Jurczak, et al. · New England Journal of Medicine · 789
PDF
Antibody-Drug Conjugates in Cancer Therapy
2012 · Eric L. Sievers, Peter D. Senter · Annual Review of Medicine · 770
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
2012 · Peter D Senter, Eric L Sievers · Nature Biotechnology · 763
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
2015 · Craig H Moskowitz, Auayporn Nademanee, et al. · The Lancet · 742
PDF
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
2018 · Steven Horwitz, Owen A O'Connor, et al. · The Lancet · 739
Antibody–drug conjugates: targeted drug delivery for cancer
2010 · Stephen C Alley, Nicole M Okeley, et al. · Current Opinion in Chemical Biology · 656
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
2019 · Jonathan E. Rosenberg, Peter H. O’Donnell, et al. · Journal of Clinical Oncology · 643
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
2017 · H Miles Prince, Youn H Kim, et al. · The Lancet · 588
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
2015 · Robert P Lyon, Tim D Bovee, et al. · Nature Biotechnology · 557
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
2020 · Nancy U. Lin, Virginia Borges, et al. · Journal of Clinical Oncology · 542
PDF
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
2005 · Svetlana O. Doronina, Brian A. Mendelsohn, et al. · Bioconjugate Chemistry · 515
Works count: 1,421
Citation count: 280,300
Year
Topic
Type